CDK9 and acute myeloid leukemia: Among the few other CDKs inhibitors being tested we outline here the CDK9 inhibitor Voruciclib in a Phase I trial in subjects with relapsed and/or refractory B cell malignancies or AML after failure of prior standard therapies alone or in combination with venetoclax (NCT03547115).